Moderate to Severe Atopic Dermatitis Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Jiangsu vcare pharmaceutical technology co., LTD, Shanghai Chia Tai Tianqing Ph

Moderate to Severe Atopic Dermatitis Pipeline constitutes 45+ key companies continuously working towards developing 50+ Moderate to Severe Atopic Dermatitis treatment therapies, analyzes DelveInsight.

Moderate to Severe Atopic Dermatitis Overview:

Atopic dermatitis (AD) is a chronic inflammatory skin condition that often begins in infancy and is characterized by dry skin, eczematous lesions, and lichenification. It is commonly associated with allergic rhinitis, asthma, and food allergies, forming part of the atopic triad.

The prevalence of AD has been rising, imposing a significant burden on patients. Moderate to severe AD presents with recurring flare-ups, intense itching, thickened or discolored skin, and raised bumps, often leading to sleep disturbances, anxiety, depression, and social stigma.

AD results from genetic and environmental factors that disrupt the skin barrier and immune response. Filaggrin mutations-affecting skin hydration-are commonly linked to AD and other allergic conditions. Environmental triggers, such as food allergies (e.g., eggs, milk, peanuts) and smoking, can worsen symptoms, making management challenging.

Effective treatment requires a comprehensive approach, including skincare routines, medications, and lifestyle modifications, to control flare-ups and enhance quality of life.

Request for a detailed insights report on Moderate to Severe Atopic Dermatitis pipeline insights @ https://www.delveinsight.com/report-store/moderate-to-severe-atopic-dermatitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Moderate to Severe Atopic Dermatitis Pipeline Insight 2024" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Moderate to Severe Atopic Dermatitis Therapeutics Market.

Key Takeaways from the Moderate to Severe Atopic Dermatitis Pipeline Report

DelveInsight's Moderate to Severe Atopic Dermatitis pipeline report depicts a robust space with 45+ active players working to develop 50+ pipeline therapies for Moderate to Severe Atopic Dermatitis treatment.
Key Moderate to Severe Atopic Dermatitis companies such as Jiangsu vcare pharmaceutical technology co., LTD, Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd., Nektar Therapeutics, E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd., Corvus Pharmaceuticals, Inc., UCB Biopharma SRL, Tavotek Biotherapeutics, Guangdong Hengrui Pharmaceutical Co., Ltd, SCM Lifescience Co., LTD., Sanofi, Amgen, Qurient Co., Ltd., Sun Pharmaceutical Industries Limited, Pfizer, UNION therapeutics, Bio-Thera Solutions, medac GmbH, Eli Lilly and Company, AbbVie, Lynk Pharmaceuticals Co., Ltd, LEO Pharma, Guangzhou JOYO Pharma Co., Ltd, Beijing InnoCare Pharma Tech Co., Ltd., Oneness Biotech Co., Ltd., Evommune, Inc., and others are evaluating new drugs for Moderate to Severe Atopic Dermatitis to improve the treatment landscape.
Promising Moderate to Severe Atopic Dermatitis pipeline therapies in various stages of development include VC005, TQH2722, Rezpegaldesleukin, QY201, Soquelitinib, and others.

Recent breakthroughs in the Moderate to Severe Atopic Dermatitis Pipeline Segment:

In September 2024, the U.S. Food and Drug Administration (FDA) approved Eli Lilly's injectable drug, Ebglyss, for individuals aged 12 and older with moderate to severe eczema. This approval was based on studies involving over 1,000 patients who had inadequate responses to other treatments. Ebglyss offers a once-monthly dosing regimen, targeting and neutralizing the IL-13 protein implicated in eczema progression.
Pfizer's Cibinqo received FDA approval in January 2022 for treating moderate to severe atopic dermatitis in adults and adolescents aged 12 and older. The approval was supported by five clinical trials involving over 1,600 patients, demonstrating significant improvements in skin clearance and rapid itch relief.
In April 2024, the FDA approved Selarsdi, a biosimilar to Stelara (ustekinumab), developed by Alvotech and Teva. This approval adds to the available biologic treatments for moderate to severe atopic dermatitis, offering more options for patients.

Moderate to Severe Atopic Dermatitis Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Moderate to Severe Atopic Dermatitis Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Moderate to Severe Atopic Dermatitis treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Moderate to Severe Atopic Dermatitis market.

Download our free sample page report on Moderate to Severe Atopic Dermatitis pipeline insights @ https://www.delveinsight.com/sample-request/moderate-to-severe-atopic-dermatitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Moderate to Severe Atopic Dermatitis Emerging Drugs

VC005: Jiangsu vcare pharmaceutical technology co., LTD
TQH2722: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Rezpegaldesleukin: Nektar Therapeutics
QY201: E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.
Soquelitinib: Corvus Pharmaceuticals, Inc.

Moderate to Severe Atopic Dermatitis Companies

Around 45 or more key companies are actively working on developing therapies for moderate to severe atopic dermatitis. Among them, Jiangsu Vcare Pharmaceutical Technology Co., LTD. has a drug candidate in the most advanced stage, Phase III clinical trials.

DelveInsight's report covers around 50+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Moderate to Severe Atopic Dermatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Moderate to Severe Atopic Dermatitis Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Moderate to Severe Atopic Dermatitis Therapies and Key Companies: Moderate to Severe Atopic Dermatitis Clinical Trials and advancements @ https://www.delveinsight.com/report-store/moderate-to-severe-atopic-dermatitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Moderate to Severe Atopic Dermatitis Pipeline Therapeutic Assessment
• Moderate to Severe Atopic Dermatitis Assessment by Product Type
• Moderate to Severe Atopic Dermatitis By Stage
• Moderate to Severe Atopic Dermatitis Assessment by Route of Administration
• Moderate to Severe Atopic Dermatitis Assessment by Molecule Type

Download Moderate to Severe Atopic Dermatitis Sample report to know in detail about the Moderate to Severe Atopic Dermatitis treatment market @ Moderate to Severe Atopic Dermatitis Therapeutic Assessment @ https://www.delveinsight.com/sample-request/moderate-to-severe-atopic-dermatitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. Moderate to Severe Atopic Dermatitis Current Treatment Patterns
4. Moderate to Severe Atopic Dermatitis - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Moderate to Severe Atopic Dermatitis Late-Stage Products (Phase-III)
7. Moderate to Severe Atopic Dermatitis Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Moderate to Severe Atopic Dermatitis Discontinued Products
13. Moderate to Severe Atopic Dermatitis Product Profiles
14. Moderate to Severe Atopic Dermatitis Key Companies
15. Moderate to Severe Atopic Dermatitis Key Products
16. Dormant and Discontinued Products
17. Moderate to Severe Atopic Dermatitis Unmet Needs
18. Moderate to Severe Atopic Dermatitis Future Perspectives
19. Moderate to Severe Atopic Dermatitis Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Moderate to Severe Atopic Dermatitis Pipeline Reports Offerings: https://www.delveinsight.com/report-store/moderate-to-severe-atopic-dermatitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.